检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:于泳[1] 张林林[2] 秦治刚[2] 武月婷[2] 谢凤洋 杨煜[3]
机构地区:[1]吉林大学白求恩医学院,长春130021 [2]吉林大学公共卫生学院,长春130021 [3]吉林大学基础医学院医学生物实验中心,长春130021
出 处:《中国免疫学杂志》2015年第8期1053-1055,1059,共4页Chinese Journal of Immunology
摘 要:目的:研究中药制剂丹参酮(TA)和抗肿瘤药物的卡铂(CA)联合应用对黑色素细胞瘤的抑制作用。方法:建立肿瘤模型后,分为模型组、丹参酮组、卡铂组、丹参酮+卡铂组,同时设立正常鼠为空白组。不同组别的小鼠分别给予腹腔注射PBS、丹参酮、卡铂、丹参酮和卡铂,空白组小鼠不做任何处理。结果:丹参酮+卡铂组小鼠的肿瘤体积和肿瘤质量显著小于丹参酮组、卡铂组和模型组(P<0.05);卡铂组小鼠的肿瘤体积和肿瘤质量显著小于丹参组和模型组(P<0.05);丹参酮+卡铂组小鼠体重增加显著好于丹参酮组和卡铂组(P<0.05)。结论:丹参酮和卡铂联合用药可以产生更好地抑制B16黑色素瘤增殖的效果。Objective: To investigate the inhibitory effects produced by combination of carboplatin( CA) and Tanshinone( TA)on the growth of B16. Methods: After the mice were injected B16 subcutaneously in the right thigh,the mice were divided into four groups,PBS group,TA group,CA group,and TA + CA group. Normal mice were set up as control. Mice of PBS group were injected 0. 2ml PBS intraperitoneally; mice of CA group were injected 0. 5 mg CA intraperitoneally for four consecutive days and followed by four days without administration until the mice were killed; mice of CA + TA group were injected 0. 5 mg CA intraperitoneally for four consecutive days and followed by four days without administration,TA( 0. 5 g / kg body weight) was administered to the mice through gastric injection every day until the mice were killed. Results: The tumor weight and volume of CA + TA mice were significantly smaller than those of CA mice,TA mice and PBS mice( P〈0. 05); the tumor weight and volume of CA mice were significantly smaller than those of TA mice and PBS mice( P〈0. 05). The body weight grow of TA + CA mice was more significant than that of TA mice and CA mice( P〈0. 05). Conclusion: Combination of carboplatin( CA) and Tanshinone( TA) will produce a better inhibitory effects on the growth of B16 cells.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222